Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOPTIN vs FROVATRIPTAN SUCCINATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Verapamil inhibits calcium ion influx across cardiac and vascular smooth muscle cells, blocking L-type calcium channels, leading to vasodilation and reduced myocardial contractility and conduction velocity.
Selective 5-HT1B/1D receptor agonist; causes vasoconstriction of intracranial extracerebral blood vessels and inhibits nociceptive trigeminal nerve transmission.
Treatment of hypertension,Management of angina pectoris,Control of supraventricular tachyarrhythmias (e.g., atrial fibrillation, atrial flutter, PSVT),Off-label: Cluster headache prophylaxis, prevention of migraine, bipolar disorder (manic episodes),Off-label: Hypertrophic cardiomyopathy (obstructive)
Acute treatment of migraine with or without aura in adults
Initial dose: 80-120 mg orally three times daily; sustained-release: 120-240 mg orally once daily. IV: 5-10 mg slow IV push over 2 minutes, may repeat after 15-30 minutes. Maximum daily oral dose: 480 mg.
2.5 mg orally once, may repeat after 2 hours if needed; maximum 7.5 mg in 24 hours.
Terminal elimination half-life: 4.5-12 hours (mean 8 hours); increases with hepatic impairment or cirrhosis
Terminal elimination half-life is approximately 4-5 hours (range 3-6 hours). This relatively short half-life supports its use for acute migraine treatment, though it may allow for repeat dosing within 24 hours if necessary.
Extensively metabolized in the liver via CYP3A4, CYP3A5, and CYP1A2 isoenzymes; major metabolite is norverapamil (active).
Primarily hepatic via CYP1A2; undergoes oxidative metabolism; some contribution from CYP2D6.
Renal (70% as metabolites, 3-5% unchanged); biliary/fecal (25%)
Primarily hepatic metabolism via CYP1A2; renal excretion accounts for ~10% of unchanged drug. Total recovery in urine and feces is ~90% over 72 hours, with ~30% in urine (mostly metabolites) and ~60% in feces.
90% bound to albumin
Approximately 30% bound to plasma proteins, primarily albumin. Low protein binding suggests minimal displacement interactions.
4.5 L/kg (extensive tissue distribution, reflects high myocardial and vascular binding)
Mean volume of distribution is approximately 2.7 L/kg, indicating extensive extravascular distribution, consistent with its CNS penetration for migraine relief.
Oral: 20-35% (extensive first-pass hepatic metabolism)
Oral bioavailability is approximately 30% due to first-pass metabolism. No other routes are clinically approved; the drug is only available orally.
For Cr Cl <30 m L/min: Reduce dose by 50-75% of normal. For Cr Cl 30-50 m L/min: Start at lower end of dosing range. No specific guidelines for dialysis.
Contraindicated in severe renal impairment (Cr Cl <15 m L/min). For moderate impairment (Cr Cl 15-29 m L/min), maximum dose 2.5 mg per 24 hours. No adjustment for mild impairment.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50% and monitor. Child-Pugh C: Use with caution, reduce dose by 70-80%.
Contraindicated in moderate to severe hepatic impairment (Child-Pugh class B or C). For mild impairment (Child-Pugh class A), no dose adjustment required.
Oral: 4-8 mg/kg/day in 3-4 divided doses; maximum 360 mg/day. IV: 0.1-0.3 mg/kg/dose (max 5 mg) over 2 minutes, repeat after 30 minutes if needed.
Safety and efficacy not established in pediatric patients under 18 years of age.
Start at lower end of dosing range (e.g., 40 mg orally three times daily); titrate slowly due to increased sensitivity and decreased clearance. Monitor for hypotension and bradycardia.
No specific dose adjustment recommended based on age alone, but use with caution due to increased risk of adverse effects (e.g., cardiovascular events) and potential age-related renal impairment.
No FDA black box warning.
Not recommended for use in patients with risk factors for coronary artery disease (CAD) unless a cardiovascular evaluation confirms absence of CAD.
Heart failure: May worsen or precipitate heart failure due to negative inotropic effects.,Hypotension: Can cause symptomatic hypotension.,Conduction abnormalities: May worsen AV block, sinus node dysfunction (risk of bradycardia).,Hepatic impairment: Reduced clearance requires dose adjustment.,Concomitant beta-blockers: Additive negative inotropic and bradycardic effects.,Digoxin: Increases digoxin levels; monitor toxicity.,Neuromuscular disorders: May exacerbate myasthenia gravis or Duchenne muscular dystrophy.,Lactation: Excreted in breast milk; caution advised.
Serious cardiac events including myocardial ischemia, infarction, and arrhythmias; cerebrovascular events including stroke; serotonin syndrome when coadministered with serotonergic drugs; increases in blood pressure; peripheral vascular ischemia; medication overuse headache; severe hepatic impairment.
Severe left ventricular dysfunction (ejection fraction <30%) or cardiogenic shock,Hypersensitivity to verapamil or any component of the formulation,Sick sinus syndrome or second/third-degree AV block (except with functioning pacemaker),Atrial flutter or fibrillation with accessory bypass tract (e.g., WPW syndrome) unless ventricular preexcitation is excluded,Concomitant use of IV beta-blockers (within a few hours),Severe hypotension (systolic <90 mm Hg)
Ischemic heart disease; history of myocardial infarction; coronary artery vasospasm; uncontrolled hypertension; hemiplegic or basilar migraine; concomitant use with ergotamines or 5-HT1 agonists; severe hepatic impairment; hypersensitivity to frovatriptan.
Grapefruit and grapefruit juice increase verapamil levels, increasing risk of toxicity. Avoid concurrent consumption. Alcohol may exacerbate hypotension and dizziness.
No specific food interactions. Avoid alcohol as it can exacerbate migraine and increase sedation risk. Grapefruit juice may increase frovatriptan levels due to CYP1A2 inhibition; limit or avoid consumption.
INSUFFICIENT DATA IN HUMANS: Animal studies show no teratogenic effects at clinically relevant doses. First trimester: case reports not indicating major malformations but risk cannot be excluded. Second/third trimester: may cause fetal bradycardia, hypotension, and intrauterine growth restriction due to placental hypoperfusion; avoid use near term due to risk of uterine atony.
Pregnancy Category C. No adequate well-controlled studies in pregnant women. In animal studies, frovatriptan caused fetal toxicity (decreased fetal weight, increased skeletal variations) at doses ≥50 mg/kg/day (approximately 100 times the MRHD). Increased risk of maternal toxicity (reduced weight gain) at high doses. Potential risk of uterine contractions and reduced uterine blood flow due to vasoconstrictive properties. Use only if potential benefit justifies risk to fetus.
Verapamil (ISOPTIN) is excreted into human breast milk with a milk-to-plasma ratio of approximately 0.6. Limited data suggest low infant doses (estimated 0.1-1% of maternal weight-adjusted dose); caution advised, especially in preterm or ill infants.
Excreted in rat milk; no human data. M/P ratio unknown. Caution recommended due to potential adverse effects in nursing infants (e.g., vasoconstriction, serotonin syndrome). Decision to breastfeed or discontinue drug should consider importance of drug to mother.
Pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced clearance) may require dose titration; no specific recommended dose adjustment, but clinical efficacy and toxicity should guide dosing; consider starting at lower doses and titrating to effect.
No specific pharmacokinetic studies in pregnancy. Dose adjustment not established; use lowest effective dose. Caution in third trimester due to possible uterine vasoconstriction. Consider alternative therapy if frequent use needed.
IV verapamil (Isoptin) can cause hypotension and bradycardia; have calcium gluconate at bedside to reverse. Avoid in patients with pre-existing heart block or systolic heart failure. Use ECG monitoring during IV administration. In atrial fibrillation, may convert to sinus rhythm but risk of ventricular preexcitation with WPW syndrome.
Frovatriptan has a long half-life (~26 h), making it useful for prolonged migraine attacks or for menstrual migraine prophylaxis when dosed perimenstrually. Onset is slower than other triptans; not ideal for acute severe migraine requiring rapid relief. Contraindicated with MAOIs, potent CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin), and within 24 h of another triptan or ergotamine. Avoid in patients with hemiplegic or basilar migraine, ischemic heart disease, or uncontrolled hypertension.
Do not stop taking suddenly; may cause chest pain or irregular heartbeat.,Avoid grapefruit and grapefruit juice while taking this medication.,Do not drink alcohol; may increase dizziness and drops in blood pressure.,Take with food or milk if stomach upset occurs.,Report slow or irregular heartbeat, shortness of breath, or swelling of ankles.
Take frovatriptan at the first sign of a migraine headache, not during the aura or for prevention of typical migraines.,Swallow tablets whole with water; do not crush or chew.,If the headache returns after initial relief, a second dose may be taken after at least 2 hours, with a maximum of 3 tablets per 24 hours.,Do not use frovatriptan if you have taken another triptan or ergotamine within the last 24 hours.,Seek emergency medical attention if you experience chest pain, shortness of breath, irregular heartbeat, or signs of serotonin syndrome (e.g., agitation, hallucinations, rapid heart rate, fever, muscle stiffness).,Avoid alcohol during use as it may worsen headache or increase side effects.,Inform your doctor if you are pregnant, breastfeeding, or have liver or kidney disease.,Do not drive or operate machinery until you know how frovatriptan affects you, as it may cause dizziness or drowsiness.
No interactions on record
"Frovatriptan, a serotonin 5-HT1B/1D receptor agonist used for acute migraine, and chlorpromazine, a first-generation antipsychotic with potent dopamine D2 receptor antagonism, can lead to additive serotonin excess when co-administered due to their combined serotonergic activity. Chlorpromazine also possesses weak serotonin reuptake inhibition properties, increasing the risk of serotonin syndrome, a potentially life-threatening condition characterized by neuromuscular excitation, autonomic instability, and altered mental status. Additionally, chlorpromazine may antagonize the vasoconstrictive effects of triptans via alpha-adrenergic blockade, potentially reducing migraine relief efficacy."
"Frovatriptan, a triptan used for migraine, is primarily metabolized by CYP1A2. Clotrimazole, an azole antifungal, inhibits CYP1A2, thereby reducing the clearance of frovatriptan. This can lead to increased systemic exposure to frovatriptan, potentially elevating the risk of triptan-related adverse effects such as serotonin syndrome, coronary vasospasm, and hypertension."
"Coadministration of frovatriptan, a serotonin receptor agonist metabolized primarily by CYP1A2, with simeprevir, a potent CYP3A4 inhibitor and weak CYP1A2 inducer, may result in reduced clearance of simeprevir due to competitive inhibition of CYP3A4 by frovatriptan or its metabolites. This interaction can lead to increased simeprevir plasma concentrations, elevating the risk of hepatotoxicity, photosensitivity reactions, and QT prolongation. Conversely, frovatriptan exposure is not significantly altered as its metabolism via CYP1A2 is minimally affected by simeprevir."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOPTIN vs FROVATRIPTAN SUCCINATE, answered by our medical review team.
ISOPTIN is a Calcium Channel Blocker that works by Verapamil inhibits calcium ion influx across cardiac and vascular smooth muscle cells, blocking L-type calcium channels, leading to vasodilation and reduced myocardial contractility and conduction velocity.. FROVATRIPTAN SUCCINATE is a 5-HT1 Agonist that works by Selective 5-HT1B/1D receptor agonist; causes vasoconstriction of intracranial extracerebral blood vessels and inhibits nociceptive trigeminal nerve transmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOPTIN and FROVATRIPTAN SUCCINATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOPTIN is: Initial dose: 80-120 mg orally three times daily; sustained-release: 120-240 mg orally once daily. IV: 5-10 mg slow IV push over 2 minutes, may repeat after 15-30 minutes. Maximum daily oral dose: 480 mg.. The standard adult dose of FROVATRIPTAN SUCCINATE is: 2.5 mg orally once, may repeat after 2 hours if needed; maximum 7.5 mg in 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOPTIN and FROVATRIPTAN SUCCINATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOPTIN is classified as Category C. INSUFFICIENT DATA IN HUMANS: Animal studies show no teratogenic effects at clinically relevant doses. First trimester: case reports not indicating major malformations but risk cann. FROVATRIPTAN SUCCINATE is classified as Category D/X. Pregnancy Category C. No adequate well-controlled studies in pregnant women. In animal studies, frovatriptan caused fetal toxicity (decreased fetal weight, increased skeletal varia. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.